title: [Gemcitabine concurrent with radiation for locally advanced pancreatic cancer].
abstract: Gemcitabine (GEM) concurrent with radiation is clinically not well defined. We herein report four cases of chemo-radiotherapy against locally advanced pancreatic cancer using low-dose GEM concurrent with extra-beam radiation. A total of eight cases entered the study. Three were resected and five were non-resected cases. Intraoperative radiation was carried out in every case using an 8 or 10 centimeter cone with a radiation dose of 25 Gy. Postoperative radiation was 2 Gy per day on weekdays for 5 weeks. Four cases were concurrent with low-dose GEM (40 mg/m2) twice a week, whereas the other four were radiation only. With the use of GEM concurrent with radiation, tumor markers decreased more than 80 percent regardless of the tumor resection. CT scan confirmed a necrotic change and the decrease of the tumor size. In conclusion, low dose GEM concurrent with radiation therapy may be a promising therapeutic choice for the local control of advanced pancreatic cancers.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Baba
authors.forename: Yozo
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Toshiya
authors.initials: T
authors.lastname: Ema
authors.forename: Masayo
authors.initials: M
authors.lastname: Kawakami
authors.forename: Chikashi
authors.initials: C
authors.lastname: Nakanishi
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Arai
authors.forename: Gaku
authors.initials: G
authors.lastname: Matsumoto
authors.forename: Koji
authors.initials: K
authors.lastname: Tsuruta
authors.forename: Atsutake
authors.initials: A
authors.lastname: Okamoto
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Karasawa
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000628:therapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine